Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with JustStocks about clinical plans for 2024

Imugene Ltd (ASX: IMU) CEO Leslie Chong talks JustStocks through the company’s clinical plans and priorities for 2024. The clinical-stage immuno-oncology company announced that its CD19 oncolytic virotherapy drug candidate onCARlytics has dosed the first patient in the intravenous monotherapy arm of Phase 1 clinical trial. Chong says the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours.

Articles of Interest